Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. Read more about Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells. Read more about DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. Read more about TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. Read more about Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). Read more about Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. Read more about Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. Read more about Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.
The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019. Read more about The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019.
Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma. Read more about Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma.
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. Read more about Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
